We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current SBMFF market cap is 8.54B. The company's latest EPS is CNY 0.1240 and P/E is 3.63.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 24.23B | 23.65B | 26.86B | 28.78B | 27.98B |
| Operating Income | 5.42B | 4.43B | 18.06B | 5.96B | 5.74B |
| Net Income | 2.76B | 2.77B | 14.61B | 2.54B | 2.33B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 37.51B | 47.21B | 60.54B | 64.06B | 63.6B |
| Total Liabilities | 16.95B | 24.79B | 22.81B | 26.12B | 25.43B |
| Total Equity | 20.56B | 22.42B | 37.73B | 37.94B | 38.17B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 5.32B | 5.33B | 5.37B | 6.27B | 6.07B |
| Investing | -3.82B | -7.85B | -2.52B | -4.07B | -756.98M |
| Financing | 2.8B | 2.23B | -3.23B | -3.19B | -6.55B |
| Market Cap | 8.54B |
| Price to Earnings Ratio | 3.63 |
| Price to Sales Ratio | 0.3 |
| Price to Cash Ratio | 0.9 |
| Price to Book Ratio | 0.22 |
| Dividend Yield | 205.75% |
| Shares Outstanding | 18.8B |
| Average Volume (1 week) | 555 |
| Average Volume (1 Month) | 8.15k |
| 52 Week Change | 13.50% |
| 52 Week High | 0.473 |
| 52 Week Low | 0.3112 |
| Spread (Intraday) | 0.08 (17.27%) |
| Company Name | Sino Biopharmaceutical (PK) |
| Address |
codan trust company (cayman) limited grand cayman KY1-1111 |
| Website | https://www.sinobiopharm.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
